Post-approval indications and clinical trials for cardiovascular drugs and some implications of the US inflation reduction act

ConclusionsPost-approval FDA indication approvals and clinical trial starts and primary completion dates often occurred after or near new DPNP selection and MFP implementation dates. This has economic consequences for future investment incentives. Post-approval trials for small molecules, longer-duration trials, and larger-enrollment trials, and post-approval indications focused on limited patient populations and older patients could face particular economic challenges.PMID:38419523 | DOI:10.1080/13696998.2024.2323903
Source: Journal of Medical Economics - Category: Health Management Authors: Source Type: research